JNCE · Jounce Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $103.27M | $88.98M | $78.69M | $67.14M | $70.05M | $34.90M |
| SG&A | $30.97M | $28.98M | $28.77M | $27.92M | $26.44M | $16.76M |
| Total Operating Expenses | $134.24M | $117.96M | $107.46M | $95.06M | $96.50M | $51.66M |
| D&A | $2.09M | $2.83M | $3.40M | $3.85M | $3.83M | $1.94M |
| Operating Income | ($52.24M) | ($91.06M) | ($45.12M) | $52.82M | ($31.29M) | ($14.47M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $135.0K | $15.0K | $14.0K | $46.0K | $46.0K | $0 |
| Net Income | ($50.92M) | ($90.87M) | ($43.84M) | $56.82M | ($27.38M) | ($13.70M) |
| EPS - Basic | ($0.99) | ($1.82) | ($1.24) | ($0.84) | - | - |
| EPS - Diluted | ($0.99) | ($1.82) | ($1.24) | ($0.84) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $150.57M | $95.53M | $147.49M | $53.24M | $47.91M | $2.34M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.10M | $1.67M | $2.04M | $2.46M | $3.27M | $2.85M |
| Current Assets | $197.23M | $190.83M | $211.39M | $173.70M | $192.21M | $255.60M |
| Total Assets | $212.55M | $252.70M | $244.24M | $205.88M | $214.45M | $296.66M |
| Current Liabilities | $23.57M | $18.90M | $19.32M | $14.40M | $65.55M | $62.55M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $29.44M | $28.89M | $32.94M | $31.29M | $110.32M | $129.55M |
| Stockholders' Equity | $183.11M | $223.81M | $211.29M | $174.59M | $104.13M | ($28.00M) |
| Retained Earnings | ($292.79M) | ($241.87M) | ($151.00M) | ($107.16M) | ($163.91M) | ($89.61M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($28.88M) | ($83.49M) | ($27.79M) | ($30.13M) | ($63.61M) | $179.69M |
| Investing Cash Flow | $83.48M | ($60.51M) | $51.30M | $31.38M | $86.41M | ($215.51M) |
| Financing Cash Flow | $442.0K | $92.04M | $70.74M | $4.08M | $1.55M | $35.51M |
| CapEx | $919.0K | $373.0K | $94.0K | $985.0K | $1.36M | $2.22M |
| Free Cash Flow | ($29.80M) | ($83.87M) | ($27.88M) | ($31.11M) | ($64.97M) | $177.47M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.59 | 0.92 | 0.64 | -0.55 | 2.37 | -12.95 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | 0.1% | - | - |
| Return on assets | -24.0% | -36.0% | -18.0% | 27.6% | -12.8% | -4.6% |
| Return on equity | -27.8% | -40.6% | -20.7% | 32.5% | -26.3% | 48.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.37 | 10.10 | 10.94 | 12.06 | 2.93 | 4.09 |
| Quick ratio | 8.37 | 10.10 | 10.94 | 12.06 | 2.93 | 4.09 |
| Cash ratio | 6.39 | 5.05 | 7.63 | 3.70 | 0.73 | 0.04 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.16 | 1.13 | 1.16 | 1.18 | 2.06 | -10.60 |
| Liabilities / Assets | 0.14 | 0.11 | 0.13 | 0.15 | 0.51 | 0.44 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 42.6% | -101.8% | - | - | -116.3% | - |
| Net income growth (YoY) | 44.0% | -107.3% | - | - | -99.8% | - |
| EPS growth (YoY) | 45.6% | -46.8% | -47.6% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 64.5% | -200.8% | 10.4% | 52.1% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -18.2% | 5.9% | 21.0% | 67.7% | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Jounce Therapeutics against the 5 most active filers in the same SIC group.